Literature DB >> 23905013

Utilizing signature-score to identify oncogenic pathways of cholangiocarcinoma.

Tzu-Hung Hsiao1, Hung-I Harry Chen, Jo-Yang Lu, Pei-Ying Lin, Charles Keller, Sarah Comerford, Gail E Tomlinson, Yidong Chen.   

Abstract

Extracting maximal information from gene signature sets (GSSs) via microarray-based transcriptional profiling involves assigning function to up and down regulated genes. Here we present a novel sample scoring method called Signature-score (S-score) which can be used to quantify the expression pattern of tumor samples from previously identified gene signature sets. A simulation result demonstrated an improved accuracy and robustness by S-score method comparing with other scoring methods. By applying the S-score method to cholangiocarcinoma (CAC), an aggressive hepatic cancer that arises from bile ducts cells, we identified enriched oncogenic pathways in two large CAC data sets. Thirteen pathways were enriched in CAC compared with normal liver and bile duct. Moreover, using S-score, we were able to dissect correlations between CAC-associated oncogenic pathways and Gene Ontology function. Two major oncogenic clusters and associated functions were identified. Cluster 1, which included beta-catenin and Ras, showed a positive correlation with the cell cycle, while cluster 2, which included TGF-beta, cytokeratin 19 and EpCAM was inversely correlated with immune function. We also used S-score to identify pathways that are differentially expressed in CAC and hepatocellular carcinoma (HCC), the more common subtype of liver cancer. Our results demonstrate the utility and effectiveness of S-score in assigning functional roles to tumor-associated gene signature sets and in identifying potential therapeutic targets for specific liver cancer subtypes.

Entities:  

Keywords:  S-score method; gene signature set; pathway analysis; tumor classification

Year:  2013        PMID: 23905013      PMCID: PMC3725832          DOI: 10.3978/j.issn.2218-676X.2012.12.04

Source DB:  PubMed          Journal:  Transl Cancer Res        ISSN: 2218-676X            Impact factor:   1.241


  33 in total

1.  Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers.

Authors:  Tanios Bekaii-Saab; Mitch A Phelps; Xiaobai Li; Motoyasu Saji; Laura Goff; John Sae Wook Kauh; Bert H O'Neil; Stephanie Balsom; Catherine Balint; Ryan Liersemann; Vasily V Vasko; Mark Bloomston; William Marsh; L Austin Doyle; Gilian Ellison; Michael Grever; Matthew D Ringel; Miguel A Villalona-Calero
Journal:  J Clin Oncol       Date:  2011-04-25       Impact factor: 44.544

2.  A pathway-based classification of human breast cancer.

Authors:  Michael L Gatza; Joseph E Lucas; William T Barry; Jong Wook Kim; Quanli Wang; Matthew D Crawford; Michael B Datto; Michael Kelley; Bernard Mathey-Prevot; Anil Potti; Joseph R Nevins
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-24       Impact factor: 11.205

3.  Distinction between hepatocellular carcinoma, cholangiocarcinoma, and metastatic carcinoma based on immunohistochemical staining for carcinoembryonic antigen and for cytokeratin 19 on paraffin sections.

Authors:  A J Balaton; M Nehama-Sibony; C Gotheil; P Callard; E E Baviera
Journal:  J Pathol       Date:  1988-12       Impact factor: 7.996

4.  Immunohistochemical and mutational analyses of Wnt signaling components and target genes in intrahepatic cholangiocarcinomas.

Authors:  Noriaki Tokumoto; Satoshi Ikeda; Yasuyo Ishizaki; Takeshi Kurihara; Shinji Ozaki; Masahiko Iseki; Yosuke Shimizu; Toshiyuki Itamoto; Koji Arihiro; Masazumi Okajima; Toshimasa Asahara
Journal:  Int J Oncol       Date:  2005-10       Impact factor: 5.650

5.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

6.  Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma.

Authors:  S Furubo; K Harada; T Shimonishi; K Katayanagi; W Tsui; Y Nakanuma
Journal:  Histopathology       Date:  1999-09       Impact factor: 5.087

7.  EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma.

Authors:  Taro Yamashita; Marshonna Forgues; Wei Wang; Jin Woo Kim; Qinghai Ye; Huliang Jia; Anuradha Budhu; Krista A Zanetti; Yidong Chen; Lun-Xiu Qin; Zhao-You Tang; Xin Wei Wang
Journal:  Cancer Res       Date:  2008-03-01       Impact factor: 12.701

8.  Expression signatures of metastatic capacity in a genetic mouse model of lung adenocarcinoma.

Authors:  Don L Gibbons; Wei Lin; Chad J Creighton; Shuling Zheng; Dror Berel; Yanan Yang; Maria Gabriela Raso; Diane D Liu; Ignacio I Wistuba; Guillermina Lozano; Jonathan M Kurie
Journal:  PLoS One       Date:  2009-04-30       Impact factor: 3.240

9.  A signature-based method for indexing cell cycle phase distribution from microarray profiles.

Authors:  Hideaki Mizuno; Yoshito Nakanishi; Nobuya Ishii; Akinori Sarai; Kunio Kitada
Journal:  BMC Genomics       Date:  2009-03-30       Impact factor: 3.969

10.  Gene expression signature of fibroblast serum response predicts human cancer progression: similarities between tumors and wounds.

Authors:  Howard Y Chang; Julie B Sneddon; Ash A Alizadeh; Ruchira Sood; Rob B West; Kelli Montgomery; Jen-Tsan Chi; Matt van de Rijn; David Botstein; Patrick O Brown
Journal:  PLoS Biol       Date:  2004-01-13       Impact factor: 8.029

View more
  4 in total

1.  Hypoxia-inducible TAp73 supports tumorigenesis by regulating the angiogenic transcriptome.

Authors:  Iqbal Dulloo; Beng Hooi Phang; Rashidah Othman; Soo Yong Tan; Aadhitthya Vijayaraghavan; Liang Kee Goh; Marta Martin-Lopez; Margarita M Marques; Chun Wei Li; De Yun Wang; Maria Carmen Marín; Wa Xian; Frank McKeon; Kanaga Sabapathy
Journal:  Nat Cell Biol       Date:  2015-03-16       Impact factor: 28.824

2.  Differential network analysis reveals the genome-wide landscape of estrogen receptor modulation in hormonal cancers.

Authors:  Tzu-Hung Hsiao; Yu-Chiao Chiu; Pei-Yin Hsu; Tzu-Pin Lu; Liang-Chuan Lai; Mong-Hsun Tsai; Tim H-M Huang; Eric Y Chuang; Yidong Chen
Journal:  Sci Rep       Date:  2016-03-14       Impact factor: 4.379

3.  A simple gene set-based method accurately predicts the synergy of drug pairs.

Authors:  Yu-Ching Hsu; Yu-Chiao Chiu; Yidong Chen; Tzu-Hung Hsiao; Eric Y Chuang
Journal:  BMC Syst Biol       Date:  2016-08-26

4.  SIX1 reprograms myogenic transcription factors to maintain the rhabdomyosarcoma undifferentiated state.

Authors:  Jessica Y Hsu; Etienne P Danis; Stephanie Nance; Jenean H O'Brien; Annika L Gustafson; Veronica M Wessells; Andrew E Goodspeed; Jared C Talbot; Sharon L Amacher; Paul Jedlicka; Joshua C Black; James C Costello; Adam D Durbin; Kristin B Artinger; Heide L Ford
Journal:  Cell Rep       Date:  2022-02-01       Impact factor: 9.995

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.